{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:19:45Z","timestamp":1780571985939,"version":"3.54.1"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1590\/abd1806-4841.20164012","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T22:53:48Z","timestamp":1463007228000},"page":"187-195","source":"Crossref","is-referenced-by-count":39,"title":["Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review"],"prefix":"10.1590","volume":"91","author":[{"given":"Andrea","family":"Sisti","sequence":"first","affiliation":[{"name":"Montecatini Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sisti","sequence":"additional","affiliation":[{"name":"University of Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Oranges","sequence":"additional","affiliation":[{"name":"Marche Polytechnic University, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5339\/qmj.2013.10","article-title":"Concise review of recent studies in vitiligo","volume":"2013","author":"Allam M","year":"2013","journal-title":"Qatar Med J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"I57","DOI":"10.1186\/1755-8166-7-S1-I57","article-title":"Vitiligo: a complex disease and a complex approach","volume":"7","author":"Begum R","year":"2014","journal-title":"Mol Cytogenet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1590\/abd1806-4841.20142573","article-title":"Vitiligo - part 1","volume":"89","author":"Tarl\u00e9 RG","year":"2014","journal-title":"An Bras Dermatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00105-013-2594-1","article-title":"Off-label indications for topical tacrolimus","volume":"64","author":"Hengge UR","year":"2013","journal-title":"Hautarzt"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-4632.2012.05697.x","article-title":"Efficacy of topical calcineurin inhibitors in vitiligo","volume":"52","author":"Wong R","year":"2013","journal-title":"Int J Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.06739.x","article-title":"FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo","volume":"153","author":"Lan CC","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1067\/mjd.2002.126250","article-title":"Topical tacrolimus for repigmentation of vitiligo","volume":"47","author":"Grimes PE","year":"2002","journal-title":"J J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2230.2004.01632.x","article-title":"Topical tacrolimus for treatment of childhood vitiligo in Asians","volume":"29","author":"Kanwar AJ","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","article-title":"Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases","volume":"51","author":"Silverberg NB","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1751-7125.2008.07558.x","article-title":"Tacrolimus-induced hyperpigmentation in a patch of vitiligo","volume":"7","author":"De D","year":"2008","journal-title":"Skinmed"},{"key":"ref11","first-page":"507","article-title":"Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color","volume":"10","author":"Silverberg JI","year":"2011","journal-title":"Journal of drugs in dermatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/2229-5178.131090","article-title":"Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy","volume":"5","author":"Sahni K","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1529-8019.2008.00198.x","article-title":"Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects","volume":"21","author":"Lotti T","year":"2008","journal-title":"Dermatol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archderm.143.9.1223","article-title":"Focal acne during topical tacrolimus therapy for vitiligo","volume":"143","author":"Bakos L","year":"2007","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1684\/ejd.2009.0779","article-title":"An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo","volume":"19","author":"Stinco G","year":"2009","journal-title":"Eur J Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2340\/00015555-1740","article-title":"Treatment of Generalised Vitiligo with Tacrolimus 0.1% Ointment vs. UVB Intense Pulsed Light Phototherapy: A Pilot Study","volume":"94","author":"Hartmann A","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"ref17","first-page":"585","article-title":"Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream","volume":"94","author":"Hartmann A","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe V","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes PE","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2340\/00015555-0464","article-title":"Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study","volume":"88","author":"Hartmann A","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-4632.2009.03852.x","article-title":"Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo","volume":"48","author":"Xu AE","year":"2009","journal-title":"Int J Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/S0365-05962011000100034","article-title":"Tacrolimus 0,1% ointment in the treatment of vitiligo: a series of cases","volume":"86","author":"Tamler C","year":"2011","journal-title":"An Bras Dermatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1346-8138.2010.01067.x","article-title":"Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo","volume":"38","author":"Udompataikul M","year":"2011","journal-title":"J Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0001-7310(05)73058-1","article-title":"Vitiligo. Treatment of 12 cases with topical tacrolimus","volume":"96","author":"Almeida P","year":"2005","journal-title":"Actas Dermosifiliogr"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1346-8138.2009.00774.x","article-title":"Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo","volume":"37","author":"Lo YH","year":"2010","journal-title":"J Dermatol"},{"key":"ref26","first-page":"123","article-title":"Vitiligo, NB-UVB and tacrolimus: our experience in Naples","volume":"149","author":"Baldo A","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo","volume":"165","author":"Ho N","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000065845","article-title":"Repigmentation of vitiligo with topical tacrolimus","volume":"205","author":"Smith DA","year":"2002","journal-title":"Dermatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archderm.139.5.571","article-title":"Successful treatment of vitiligo with 0.1% tacrolimus ointment","volume":"139","author":"Travis LB","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref30","first-page":"158","article-title":"Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series","volume":"71","author":"Tanghetti EA","year":"2003","journal-title":"Cutis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1525-1470.2005.22123.x","article-title":"Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo","volume":"22","author":"Prats Caelles I","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1346-8138.2008.00511.x","article-title":"Topical immunomodulators are effective for treatment of vitiligo","volume":"35","author":"Choi CW","year":"2008","journal-title":"J Dermatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2133.2009.09217.x","article-title":"Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus","volume":"161","author":"Taher ZA","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1468-3083.2009.03138.x","article-title":"Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial","volume":"23","author":"Radakovic S","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/0019-5154.84735","article-title":"Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial","volume":"56","author":"Bhuvana K","year":"2011","journal-title":"Indian J Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v91n2\/0365-0596-abd-91-02-0187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:43Z","timestamp":1747666843000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962016000200187&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0365-05962016000200187"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.20164012","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}